What the research firmly supports: BPC-157's gut healing, vascular, and neuroprotective mechanisms (strong preclinical evidence) Thymosin Alpha-1's immune modulating and T-cell restorative effects (strong preclinical + clinical evidence in viral disease) TB-500's cardiovascular repair and angiogenic properties (strong preclinical, early human data) What the research does not yet confirm: Randomised controlled trial data specifically in long COVID populations Optimal dosing, sequencing, and duration specifically for PASC Long-term safety data for extended post-viral use This doesn't mean these peptides don't work for long COVID
In particular, LEAP2 (liver-expressed antimicrobial peptide 2), an endogenous antagonist of the ghrelin receptor GHSR, has emerged as a potential target for mitigating the weight regain often observed after discontinuation of GLP-1-based therapies [22,23]
"Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model." Annals of Clinical & Laboratory Science A study indicating the regenerative influence of AOD-9604 on joint cartilage
However, this has NOT been demonstrated specifically for BPC-157 in any published study
Clinic-Grade TB-500 vs
